Resistance treatment and optimization of cancer treatment by vectorisation of immune targeted active drug-substances

ACILIMAB est accrédité par Lyonbiopôle

Identity card

Global budget: 2820 k€

Public funding: 1447 k€

Public funders: FEDER Rhône-Alpes, Fonds Unique Interministériel (FUI) – DGCIS/Oséo, Grand Lyon, Oséo / BPI France (except FUI), Région Rhône-Alpes

Call for projects: FUI (FUI AAP12)

Year start: 2011

Completed project

Accredited by the French competitiveness cluster Lyonbiopôle

Strategic business area: Human Medicines

Application fields: Autoimmune diseases, Neurology, Oncology

Technological approaches / Keywords: Biologics, Drug delivery system, Immunotherapy, Innovative formulation, Nanobiotechnology

Stage of development at the beginning of the project: Discovery


Chemotherapies can be made more efficient and better tolerated when the active substances are concentrated and targeted to the tumours. Through ACILIMAB a new combined therapy will be developed which will combine active drug-substances, monoclonal antibodies as targeting agents, and Lipidots® as vectors. This delivery strategy will be evaluated on mantle lymphoma cells which are resistant to conventional chemotherapeutics. The aim will be to demonstrate the therapeutic efficacy of drug-loaded immuno-particles, so as to establish therapeutic alternatives for currently non-curable lymphoma.


The objectives of ACILILAB project are:- to develop a safe, easy and innovative targeted delivery of high potent therapeutic drug based on anti CD19 MAb decorated Lipidots®- to demonstrate that MAb-targeted nanoparticles are potentially useful as targeting delivery systems for chemotherapeutic agents- to acquire knowledge on immuno-nanocarriers as targeted delivery for tumour cells- to strengthen the therapeutic arsenal for patients & clinicians

Innovative assets
Actual results

Innovative assets

Through ACILIMAB new platforms were generated dedicated to the development and characterization of drug-loaded immuno-particles. Up to date active drug-substances were screened and selected regarding key parameters such as activity and loading. Futher experiments are in progress to optimize the generation, the stability, the specific cellular binding and internalisation of drug-loaded immuno-particles.